Microcap Ledger Medicinova Inc $MNOV
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- La Jolla, CA
- Fiscal year end
- December 31
- Shares outstanding
- 49,221,246 [10-Q 2026-08-13]
What the company doesAI summary of filing
MediciNova is a biopharmaceutical company developing novel therapeutics for serious diseases with unmet medical needs. The company's two lead product candidates are MN-166 (ibudilast), in clinical-stage development for neurological and other disorders including progressive multiple sclerosis, amyotrophic lateral sclerosis, degenerative cervical myelopathy, glioblastoma, and acute respiratory distress syndrome, and MN-001 (tipelukast), in clinical-stage development for fibrotic and metabolic disorders including nonalcoholic fatty liver disease and hypertriglyceridemia. MediciNova is currently pre-revenue, with no approved products for commercial sale and no product sales revenues, and relies on raising capital to fund its clinical development programs. [10-K 2026-03-10]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $645.4K | −$4.90M | −$5.39M | $25.42M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $409.7K | $12.00M | −$9.81M | $30.81M | [10-K 2026-03-10] |
| FY ended Dec 2024 | — | $11.05M | −$10.64M | $40.36M | [DEF 14A 2026-04-29] |
- Quarterly cash burn
- −$2.70M
- Cash runway Estimate
- ~28.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 49,046,246 | [10-Q 2024-11-13] |
| 2025-02-17 | 49,046,246 | [10-K 2025-02-19] |
| 2025-05-09 | 49,046,246 | [10-Q 2025-05-13] |
| 2025-08-11 | 49,046,246 | [10-Q 2025-08-14] |
| 2025-11-12 | 49,046,246 | [10-Q 2025-11-12] |
| 2026-03-05 | 49,221,246 | [10-K 2026-03-10] |
| 2026-05-12 | 49,221,246 | [10-Q 2026-05-14] |
| 2026-08-11 | 49,221,246 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2025-12-05; declared effective 2025-12-11 [S-3 2025-12-05]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-25 | 3D Investment Partners Pte. Ltd. | sell | 640,000 | $2.70 | [4 2026-09-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-09-28 | 8-K | Material agreement entered |
| 2026-09-02 | 8-K | Material agreement terminated |
| 2026-08-19 | 8-K | Director or officer change |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-06-24 | 8-K | Shareholder vote results |
| 2026-05-14 | 10-Q | Quarterly report |
| 2026-04-29 | DEF 14A | Proxy statement |
| 2026-04-17 | PRE 14A | Proxy statement |
| 2026-03-10 | 10-K | Annual report |
| 2026-02-20 | 8-K | Results of operations |
| 2025-12-30 | 424B5 | Prospectus or prospectus supplement |
Alerts for $MNOV
Email me when Medicinova Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.